Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Journal: Kidney international reports
Published: February 15, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Journal: Kidney international
Published: December 07, 2022
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Journal: Kidney international reports
Published: November 01, 2022
Interpreting clinical and laboratory tests: importance and implications of context.
Journal: Diagnosis (Berlin, Germany)
Published: February 13, 2019
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
Journal: European journal of heart failure
Published: April 14, 2017
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
Journal: European heart journal
Published: February 10, 2017
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Journal: European journal of heart failure
Published: January 11, 2016
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: June 25, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026